Cargando…

Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy

BACKGROUND: The role and technique of catheter ablation of atrial fibrillation (AF) in the elderly is unclear. While in young patients pulmonary vein isolation (PVI) has evolved as first option, in older patients decision is often made in favor of drugs as higher complication rates and less benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Willy, Kevin, Wasmer, Kristina, Dechering, Dirk G., Köbe, Julia, Lange, Philipp S., Bögeholz, Nils, Ellermann, Christian, Reinke, Florian, Frommeyer, Gerrit, Eckardt, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724234/
https://www.ncbi.nlm.nih.gov/pubmed/33073878
http://dx.doi.org/10.1002/clc.23485
_version_ 1783620503039115264
author Willy, Kevin
Wasmer, Kristina
Dechering, Dirk G.
Köbe, Julia
Lange, Philipp S.
Bögeholz, Nils
Ellermann, Christian
Reinke, Florian
Frommeyer, Gerrit
Eckardt, Lars
author_facet Willy, Kevin
Wasmer, Kristina
Dechering, Dirk G.
Köbe, Julia
Lange, Philipp S.
Bögeholz, Nils
Ellermann, Christian
Reinke, Florian
Frommeyer, Gerrit
Eckardt, Lars
author_sort Willy, Kevin
collection PubMed
description BACKGROUND: The role and technique of catheter ablation of atrial fibrillation (AF) in the elderly is unclear. While in young patients pulmonary vein isolation (PVI) has evolved as first option, in older patients decision is often made in favor of drugs as higher complication rates and less benefit are suspected. Therefore, data on PVI of paroxysmal and persistent AF in these patients is still sparse but of eminent importance. HYPOTHESIS: PVI is comparably safe in the very elderly with similar recurrence and complication rates. METHODS: We enrolled all patients (n = 146) aged >75 years who underwent a first PVI over a period of 10 years (2009‐2019) from our prospective single‐center ablation registry. Mean follow‐up time was 231 ± 399 days. RESULTS: Acute ablation success defined as complete PVI and sinus rhythm at the end of the ablation procedure was high (99%). Severe periprocedural complications occurred in 3.3% (stroke/TIA n = 2; 1.3%; pericardial effusion n = 3; 2%). In 4.6% of patients symptomatic sick‐sinus‐syndrome was unmasked after PVI resulting in pacemaker implantation. There were no deaths related to PVI. Recurrence rate of symptomatic AF was 37.3% resulting in a Re‐PVI and/or substrate ablation in 32 pts (20.9%). During follow‐up pacemaker implantation plus atrioventricular node ablation was performed in 10 pts (6.8%). There was a trend toward lower recurrence rates with single‐shot devices (cryoballoon, multielectrode phased‐radiofrequency ablation catheter) than with point‐by‐point radiofrequency while complication rates did not differ. CONCLUSION: PVI for AF is a feasible treatment option also in patients >75 years with a reasonable success and safety profile. Higher success rates occurred in patients treated with a single‐shot device as compared to point‐by‐point ablation.
format Online
Article
Text
id pubmed-7724234
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-77242342020-12-11 Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy Willy, Kevin Wasmer, Kristina Dechering, Dirk G. Köbe, Julia Lange, Philipp S. Bögeholz, Nils Ellermann, Christian Reinke, Florian Frommeyer, Gerrit Eckardt, Lars Clin Cardiol Clinical Investigations BACKGROUND: The role and technique of catheter ablation of atrial fibrillation (AF) in the elderly is unclear. While in young patients pulmonary vein isolation (PVI) has evolved as first option, in older patients decision is often made in favor of drugs as higher complication rates and less benefit are suspected. Therefore, data on PVI of paroxysmal and persistent AF in these patients is still sparse but of eminent importance. HYPOTHESIS: PVI is comparably safe in the very elderly with similar recurrence and complication rates. METHODS: We enrolled all patients (n = 146) aged >75 years who underwent a first PVI over a period of 10 years (2009‐2019) from our prospective single‐center ablation registry. Mean follow‐up time was 231 ± 399 days. RESULTS: Acute ablation success defined as complete PVI and sinus rhythm at the end of the ablation procedure was high (99%). Severe periprocedural complications occurred in 3.3% (stroke/TIA n = 2; 1.3%; pericardial effusion n = 3; 2%). In 4.6% of patients symptomatic sick‐sinus‐syndrome was unmasked after PVI resulting in pacemaker implantation. There were no deaths related to PVI. Recurrence rate of symptomatic AF was 37.3% resulting in a Re‐PVI and/or substrate ablation in 32 pts (20.9%). During follow‐up pacemaker implantation plus atrioventricular node ablation was performed in 10 pts (6.8%). There was a trend toward lower recurrence rates with single‐shot devices (cryoballoon, multielectrode phased‐radiofrequency ablation catheter) than with point‐by‐point radiofrequency while complication rates did not differ. CONCLUSION: PVI for AF is a feasible treatment option also in patients >75 years with a reasonable success and safety profile. Higher success rates occurred in patients treated with a single‐shot device as compared to point‐by‐point ablation. Wiley Periodicals, Inc. 2020-10-19 /pmc/articles/PMC7724234/ /pubmed/33073878 http://dx.doi.org/10.1002/clc.23485 Text en © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigations
Willy, Kevin
Wasmer, Kristina
Dechering, Dirk G.
Köbe, Julia
Lange, Philipp S.
Bögeholz, Nils
Ellermann, Christian
Reinke, Florian
Frommeyer, Gerrit
Eckardt, Lars
Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
title Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
title_full Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
title_fullStr Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
title_full_unstemmed Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
title_short Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
title_sort ablation of paroxysmal and persistent atrial fibrillation in the very elderly real‐world data on safety and efficacy
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724234/
https://www.ncbi.nlm.nih.gov/pubmed/33073878
http://dx.doi.org/10.1002/clc.23485
work_keys_str_mv AT willykevin ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT wasmerkristina ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT decheringdirkg ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT kobejulia ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT langephilipps ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT bogeholznils ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT ellermannchristian ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT reinkeflorian ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT frommeyergerrit ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy
AT eckardtlars ablationofparoxysmalandpersistentatrialfibrillationintheveryelderlyrealworlddataonsafetyandefficacy